ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 0738 • ACR Convergence 2021

    Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis

    Weiheng Chen1, Mengge Song1, Yan Jia1, Jigao Sun1, Yan Zhao2, Zhipeng Xue3, Qianglong Chen2, xiangrong Zeng2 and Chenchen Wang4, 1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), 22Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), 31The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), 4Tufts Medical Center, Boston, MA

    Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
  • Abstract Number: 0761 • ACR Convergence 2021

    Development of a Symptom Diary for Use in Patients with Sjogren’s Syndrome

    Briana Ndife1, Sheri Fenel2, Sandy Lewis2 and Neetu Agashivala3, 1Novartis, East Hanover, NJ, 2RTI Health Solutions, Research Triangle Park, NC, 3Novartis Pharmaceutical Corporation, East Hanover, NJ

    Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disease associated with a wide range of symptoms and long-term complications. While clinical indices are useful in…
  • Abstract Number: 0853 • ACR Convergence 2021

    A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap

    Craig Willers1, Tom Lynch1, Vibhasha Chand2, Mohammad Islam3, Marissa Lassere4, Helen Keen5, Tony Kenna6, Susan Lester7, Ranjeny Thomas8, Premarani Sinnathurai9, Mihir Wechalekar10, Ashley Fletcher11, Daniel Lightowler12, Sheeraz Mohd13, Nishta Ramnoruth14, Carlee Ruediger15, Helen Weedon16 and Lyn March17, 1Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, 2Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 3Information and Communications Technology, University of Sydney, Sydney, Australia, 4St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, 5University of Western Australia, Daglish, Australia, 6Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, 7Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, 8University of Queensland, Diamantina Institute, Brisbane, Australia, 9Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, 10Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, 11Cabrini Health, Malvern, Australia, 12Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, 13Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, 14Diamantina Institute, University of Queensland, Brisbane, Australia, 15University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, 16Flinders University, Bedford Park, Australia, 17Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia

    Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
  • Abstract Number: 1213 • ACR Convergence 2021

    Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge

    Christoph Baerwald1, Edgar Stemmler2, Sixten Gnuechtel2, Katharina Birkner2, Carsten Holland3, Bjoern Fritz2, Daniela Adolf4 and Ralf Baron5, 1University Hospital Leipzig, Leipzig, Germany, 2AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany, 3AbbVie Deutschland GmbH & Co. KG, Wiesbaden, 4StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, 5University Hospital Schleswig-Holstein, Kiel, Germany

    Background/Purpose: Pain is the symptom with the most significant impact on patients’ lives in rheumatoid arthritis (RA), whereas 17% of German RA patients report severe…
  • Abstract Number: 1334 • ACR Convergence 2021

    How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study

    Uta Kiltz1, Jan Brandt-Jrgens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, 4Department for Rheumatology and Immunology, Hannover Medical University, Hannover, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Universitätsklinikum Würzburg, Wuerzburg, Germany

    Background/Purpose: Gender disparities in PsA can affect natural course of disease, clinical presentation and response to medication1. The German non-interventional study AQUILA provides real-world data…
  • Abstract Number: 1644 • ACR Convergence 2021

    Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study

    Aviya Lanis1, Emilee Tu2, Malki Peskin3, Maryann Melendez1, Gabriel Tarshish4, Alisha Akinsete5, Alicia Hoffman1, Kathleen Kenney-Riley6, Tamar Rubinstein7 and Dawn Wahezi1, 1Children's Hospital at Montefiore, Bronx, NY, 2Albert Einstein School of Medicine, Bronx, NY, 3Montefiore, Bronx, NY, 4Children's Hospital at Montefiore, New York, NY, 5Montefiore, Wayne, NJ, 6Mercy College, Dobbs Ferry, NY, 7Albert Einstein College of Medicine, White Plains, NY

    Background/Purpose: Storytelling is a universal form of communication that allows expression of experiences. Narrative medicine can be described as a subset of storytelling in which…
  • Abstract Number: 0112 • ACR Convergence 2021

    A Randomized Trial Showing No Differences in Patient Satisfaction with Telemedicine Delivered by Phone or Video During COVID-19 in Rheumatology and Other Medical Specialty Clinics

    Maria I. Danila1, Dongmei Sun2, Lesley Jackson1, Gary Cutter1, Elizabeth Jackson1, Eric Ford1, Erin DeLaney1, Amy Mudano1, Jeffrey Foster1, Giovanna Rosas1, Jeffrey Curtis3 and Kenneth Saag1, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The COVID-19 pandemic has led to a significant shift to home-based telemedicine including video and phone-only visits in many medical specialties. However, patients may…
  • Abstract Number: 0400 • ACR Convergence 2021

    Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire

    John Pauling1, Lesley Ann Saketkoo2, Dinesh Khanna3, Christopher Denton4, Tracy Frech5, Ariane Herrick6, Laura Hummers7, Ami Shah8 and Robyn Domsic9, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 3University of Michigan, Ann Arbor, MI, 4University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 5University of Utah, Salt Lake City, UT, 6University of Manchester, Salford, United Kingdom, 7Johns Hopkins Univerisity, Baltimore, MD, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: The episodic and uniquely personalised nature of Raynaud’s phenomenon (RP) has led to reliance upon self-report to capture how patients ‘feel’ and ‘function’. Existing…
  • Abstract Number: 0739 • ACR Convergence 2021

    Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)

    Uta Kiltz1, Eerik Ahomaa2, Björn Buehring1, Xenofon Baraliakos1, David Kiefer1, Jaclyn-Dalisay Leicht1 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany

    Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
  • Abstract Number: 0762 • ACR Convergence 2021

    Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform

    Amy Boalch1, Sam Norton1, Sophia Steer2, Nicky Wilson2 and James Galloway3, 1King's College London, London, United Kingdom, 2King's College Hospital, London, United Kingdom, 3Kings College London, London, United Kingdom

    Background/Purpose: The Musculoskeletal Health Questionnaire (MSK-HQ) is a patient reported outcome measure (PROM) validated to assess disease outcomes in patients with MSK disorders. This study…
  • Abstract Number: 0860 • ACR Convergence 2021

    Associations Between Tricarboxylic Acid Cycle Plasma Metabolites and Fatigue Phenotypes in Black Females with Systemic Lupus Erythematosus: An Untargeted Metabolomics Analysis

    Laura Kimble1, Arezou Khosroshahi1, Glenna Brewster1, Nicole Carlson1, Ronald Eldridge1 and Elizabeth Corwin2, 1Emory University, Atlanta, GA, 2Columbia University, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) occurs predominantly in women and Black women have disproportionately poorer health outcomes across the trajectory of their disease compared to…
  • Abstract Number: 1214 • ACR Convergence 2021

    Examining the Relationship Between Shared Epitope, ACPA Seropositivity, and Real-World Drug Effectiveness in Patients with Rheumatoid Arthritis

    Kristin Wipfler1, Joshua Baker2, Harlan Sayles3, Xue Han4, Sang Hee Park4, Keith Wittstock4, Ted Mikuls3 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE, 4Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: The shared epitope (SE) is an amino acid sequence motif coded by several HLA-DRB1 alleles that are overrepresented among people with rheumatoid arthritis (RA).…
  • Abstract Number: 1350 • ACR Convergence 2021

    Sustained Improvement in Physical Function, Disease Impact and Health­-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study

    Laure Gossec1, Akihiko Asahina2, Alice Gottlieb3, Laura Coates4, Barbara Ink5, Deepak Assudani6, Jason Coarse7, Scarlett Hellot8, Jason Eells6 and Philip Mease9, 1Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 2Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 5UCB Celltech, Slough, UK, Slough, United Kingdom, 6UCB Pharma, Slough, United Kingdom, 7UCB Pharma, Raleigh, NC, 8UCB Pharma, Colombes, France, 9Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin…
  • Abstract Number: 1652 • ACR Convergence 2021

    Symptom Burden in Anti-citrullinated Protein Antibody Positive Individuals At-risk for Rheumatoid Arthritis Is Changing over Time and Comparable to Patients with Early Rheumatoid Arthritis

    Paul Studenic1, Alexandra Circiumaru2, Daniel Aletaha3, Katerina Chatzidionysiou4, Anca Catrina5 and Aase Haj Hensvold6, 1Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, 3Medical University Vienna, Vienna, Austria, 4Karolinska Institute, Division of Rheumatology; & Karolinska University Hospital, Rheumatology Unit, Stockholm, Sweden, 5Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 6Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden

    Background/Purpose: Symptom burden in individuals at risk for developing rheumatoid arthritis (RA) - positive for anti-citrullinated peptide antibodies (ACPA) and musculoskeletal complaints - has not…
  • Abstract Number: 0124 • ACR Convergence 2021

    Nurse-supported Web-based Cognitive Behavioral Therapy for Chronic Musculoskeletal Pain: An Effectiveness Trial

    Rami Diab1, Rebecca Bomar2, Christina Rinaldi2, Claudia Campos2, Sebastian Kaplan2 and Dennis Ang3, 1Wake Forest Baptist Health/Wake Forest School of Medicine, Winston-Salem, NC, 2Wake Forest School of Medicine / Wake Forest University Baptist Medical Center, Winston-Salem, NC, 3Wake Forest School of Medicine, Winston-Salem, NC

    Background/Purpose: Pain accounts for greater than 40% of all symptom-related outpatient visits totaling over 100 million outpatient encounters worth hundreds of billions of dollars annually…
  • « Previous Page
  • 1
  • …
  • 31
  • 32
  • 33
  • 34
  • 35
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology